KOLs vs DOLs: Which Pharma Influence Works in 2026?

Author(s): Daryna Yaremenko

For years, pharma influence was relatively easy to recognize. It lived in congress halls, advisory boards, journal publications, and the voices of respected clinical experts. If a physician, researcher, or professor shaped how others understood a therapy area, they were likely part of the KOL conversation.

That model still matters. But it no longer covers the full picture. Today, HCPs do not wait for a congress presentation or a journal issue to discover expert perspectives. They follow medical educators on LinkedIn. They attend webinars between patient consultations. They listen to podcasts, join online communities, and discuss new data in digital spaces long before a formal event takes place.

DOLs do not replace key opinion leaders, and they should not be treated as medical influencers with a larger audience. Their value lies in a different kind of influence: continuous, visible, measurable, and built through regular digital interaction.